Bayer's Nexavar gets Chinese nod; Cephalon sues Barr over Fentora patent;

> Bayer and Onyx Pharmaceuticals got approval from Chinese drug regulators to market their Nexavar drug for liver cancer. Report

> Cephalon sued Barr Pharmaceuticals for patent infringement over its Fentora cancer pain drug, after Barr asked the FDA to approve its generic version. Report

> India's Glenmark Pharmaceuticals posted a 101.9 percent increase in fiscal first-quarter profits on strong growth in its generics business. Report

> Watson Pharmaceuticals named Clare Carmichael as senior vice president for human resources, replacing Susan Skara, who retired. Release

> SiCap, an Albany-area company known for its "Sinus Buster" nasal sprays, has been acquired by Dynova Laboratories, a private-equity-funded venture. Report

> In another instance of the industry teaming up with academia, GlaxoSmithKline and Harvard Stem Cell Institute (HSCI) announced that they have signed a five-year, $25 million pact to research and possibly develop stem cell drugs. Report

> New Jersey-based nutraceutical company Integrated Biopharma is spinning off its interest in iBioPharma to form a stand-alone biotech company. Report

> CHMP announced today the recommendation of Bayer's Xarelto, known generically as rivaroxaban. Report

And Finally... Anxiety and depression double the risk of type 2 diabetes in men, a study shows. Report

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.